Clinical trials: Visual Pathway Disorder
Optic Nerve Disease, Macular Disease
Implementation of the NEDS EyeCTester App
Group 4a and 4b was an FDA trial that showed that patients who have an Amsler grid abnormality on paper, have a similar abnormality on the app.
- Conditions
- Optic Nerve Disease, Macular Disease, Visual Pathway Disorder
- Trial name
- NCT04607369
- Testing
- EyeCTester
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Neuro-Eye Diagnostic Systems, LLC
Mild Cognitive Impairment, Metabolic Syndrome
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation
The study explores whether selective memory complaints (SMC), mild cognitive impairment (MCI) and the comorbidity of Metabolic Syndrome symptomatic of peripheral and cerebral hypo-metabolism with corresponding epigenetic shifts…
- Trial name
- NCT03319173
- Testing
- Dietary intervention
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Bristlecone Health, Inc.
Relapsing Remitting Multiple Sclerosis, Optic Neuropathy
Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis
The objective of this trial is to assess the efficacy and safety of CNM-Au8 as a remyelinating treatment for vision-impairing MS lesions in participants who have chronic vision impairment as a result of Relapsing-Remitting…
- Conditions
- Relapsing Remitting Multiple Sclerosis, Optic Neuropathy, Optic; Neuritis, With Demyelination
- Trial name
- VISIONARY-MS (NCT03536559)
- Testing
- CNM-Au8
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 73 people
- Sponsor
- Clene Nanomedicine
Brain and Central Nervous System Tumors, Lymphoma
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of DX-8951f in treating children who have advanced solid…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00004212
- Testing
- filgrastim, exatecan mesylate
- Where
- 4 sites in United States
- Sponsor
- Daiichi Sankyo